Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 17/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 11/20 | 1.00 |
| ▸ | PRKACA | P17612 | 4/20 | 0.73 |
| ▸ | PRKACG | P22612 | 4/20 | 0.73 |
| ▸ | PRKACB | P22694 | 4/20 | 0.73 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18685145 | 0.90 | ROCK2 (0.81) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL17439838 | 0.89 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL18685098 | 0.89 | ROCK2 (0.80) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL17439778 | 0.89 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL18685159 | 0.85 | ROCK2 (0.75) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL17439933 | 0.85 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL3812995 | 0.85 | ROCK2 (0.76) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL1649565 | 0.84 | PRKACA (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL3249977 | 0.84 | ROCK2 (0.75) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL17439932 | 0.83 | ROCK2 (1.00) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961745-B1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | claimed |
| US-9458110-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | claimed |
| US-20160016910-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2016-01-21 | — | — | US | claimed |
| EP-2961745-B1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9458110-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160016910-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2016-01-21 | — | — | US | disclosed |
| US-9126944-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140243338-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243338-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | ROCK1, ROCK2, MYLK | ROCK2 2/4885ROCK1 1/4885PRKACA 279/4885 |
| US-20160016910-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | ROCK1, ROCK2, MYLK | ROCK2 2/4885ROCK1 1/4885PRKACA 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.